Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies
Allen, J.A (University of Minnesota)
Berger, Melvin (Immunology Research and Development, CSL Behring)
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau)
Kuitwaard, Krista (Albert Schweitzer Hospital (Països Baixos))
Hadden, Robert D. (King's College Hospital NHS Foundation Trust)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	Despite the well-recognized importance of immunoglobulin therapy individualization during the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), the pathway to best achieve optimization is unknown. There are many pharmacokinetic and immunobiologic variables that can potentially influence the appropriateness of any individual therapy. Although identification of specific autoantibodies and their targets has only been accomplished in a minority of patients with CIDP, already the diagnostic and treatment implications of specific autoantibody detection are being realized. Individual variability in IgG pharmacokinetic properties including IgG catabolic rates and distribution, as well as the IgG level necessary for disease control also require consideration during the optimization process. For optimization to be successful there must be a measure of treatment response that has a clinically meaningful interpretation. There are currently available well-defined and validated clinical assessment tools and outcome measures that are well suited for this purpose. While there remains much to learn on how best to manipulate immunopathology and immunoglobulin pharmacokinetics in the most favorable way, there currently exists an understanding of these principles to a degree sufficient to begin to develop rational and evidence-based treatment optimization strategies.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Autoimmune neuromuscular diseases ; Chronic inflammatory demyelinating polyneuropathy ; Immune-mediated neuropathies ; Intravenous immunoglobulin ; Pharmacokinetics
Publicat a:	Journal of the Peripheral Nervous System, Vol. 23 (april 2018) , p. 78-87, ISSN 1529-8027

DOI: 10.1111/jns.12262
PMID: 29573033

10 p, 813.9 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats